DSO vs Independent Sale:
The Decision Every Selling Dentist Has to Make

At some point in every dentist's career, the question stops being abstract. You've been building your practice for fifteen, twenty, maybe thirty years — and now you're actually considering selling. The number on the letterhead from the DSO acquisition team is real. The associate who has been quietly asking about buying you out is real. The decision you've been putting off is no longer hypothetical.

The choice between selling to a Dental Service Organization and selling to an independent buyer is genuinely consequential. It's not just about which offer is larger — though that matters. It's about what your life looks like after the transaction closes. How long you'll be working and under what conditions. What happens to your staff and your patients. Whether you maintain any ownership stake going forward or walk away completely. Whether the check you receive is truly the check you receive, or whether a third of it is sitting in an escrow account waiting on earnout conditions you may not fully control.

This guide is the honest comparison. Not a sales pitch for either path — both can be excellent outcomes depending on who you are and what you want. Our goal is to help you understand the real differences at a level of detail that actually helps you make the decision, negotiate the deal, and walk away from closing without regret.

Valuation Multiples: Why DSOs Usually Pay More (And What That Actually Means)

The most visible difference between a DSO offer and an independent buyer offer is usually price. DSOs — especially private equity-backed platforms — routinely offer higher valuations than individual dentists can pay, and the gap is real. A practice generating $400,000 in annual adjusted EBITDA might attract a 3–5x multiple from an independent buyer and a 5–8x multiple from a well-capitalized DSO. On paper, that's a difference of $800,000 to $1.2 million.

Understanding why DSOs can pay more helps you evaluate whether the premium is real or illusory. DSOs operate at scale: they spread administrative costs — billing, HR, marketing, credentialing, supply purchasing — across dozens or hundreds of locations. When they acquire your practice, they immediately extract margin by running those functions more cheaply than you could as a solo operator. They're also often backed by private equity that is explicitly betting on future portfolio-level exits at even higher multiples, meaning they can justify paying above market today in exchange for the upside of scale. The premium they pay you is essentially priced in advance against that future exit.

What this means practically: the DSO's headline number is almost always higher, but the after-tax, after-earnout, after-equity-roll number is what you should be comparing. A $1.6 million DSO offer with a 20% equity roll and aggressive earnout conditions may net you significantly less actual liquidity at close than a $1.2 million all-cash independent sale. Run the numbers with your accountant before you let the headline figure anchor your thinking.

Earnouts: The Part of the DSO Deal Nobody Explains Clearly Enough

The earnout is one of the most significant structural elements in a DSO transaction — and one of the most misunderstood. An earnout holds a portion of the purchase price (typically 10–25%) in escrow and releases it to you over one to three years based on the practice's post-close performance against agreed metrics. Those metrics usually involve maintaining production levels, collections thresholds, or patient retention rates above a specified baseline.

On the surface this sounds reasonable — you're being asked to stand behind the numbers you sold the practice on. The problem is that earnout performance metrics can be significantly influenced by decisions the DSO makes after closing, not just by your clinical work. If the DSO changes your fee schedule, adds or drops insurance networks, modifies scheduling protocols, brings in an associate who negatively impacts patient experience, or alters your hours — all of those affect collections and patient retention, and all of them are outside your control once you've signed over ownership. You bear the financial risk; they hold the operational levers.

This doesn't mean earnouts are inherently bad — they're a standard feature of many legitimate DSO transactions. But they need careful scrutiny. Before you sign, work through specific scenarios with your attorney: what happens to the earnout if the DSO makes operational changes that affect your numbers? Are there carve-outs that protect your earnout if performance suffers due to decisions outside your control? What are the exact metrics, and who calculates and certifies them? How is a dispute resolved? These questions are not paranoia — they're standard due diligence that any experienced dental transaction attorney will raise.

Equity Rolls: The Upside Play That Might or Might Not Pay Off

Many DSO deals — particularly those backed by private equity — offer sellers the option (sometimes the requirement) to roll a portion of their proceeds into equity in the parent platform rather than taking all cash at close. If you roll 20% of your purchase price into DSO equity and the platform later sells or goes public at a higher multiple, you participate in that upside. In theory, the "second bite of the apple" can meaningfully increase your total proceeds from the transaction.

In practice, the equity roll deserves significant scrutiny. DSO equity is illiquid — you can't sell it when you want to, and your holding period is determined by the platform's timeline for its next exit, not yours. You'll typically be looking at a 3–7 year hold before any liquidity event, if one occurs at all. Private equity-backed DSO platforms do achieve successful exits, but not every one does, and even those that do may exit at multiples that barely recover what you rolled in. Before agreeing to an equity roll, ask: what is the DSO's current enterprise value? What multiple would a future exit need to achieve for the roll to be accretive to you? How does that compare to what you could earn simply investing the cash proceeds in a diversified portfolio? These are not rhetorical questions — they have real answers, and you should know what those answers are before you agree to the structure.

Clinical Autonomy: The Honest Conversation About What Changes

The most common concern dentists raise about DSO affiliation is clinical autonomy — and it's a legitimate concern, though the reality varies enormously from one DSO to another. The DSO landscape in 2026 is not monolithic. Large national platforms manage hundreds of locations and tend to have more standardized protocols; smaller regional DSOs, particularly doctor-founded ones, often operate with a genuinely light touch on clinical decisions. The management services agreement is the document that tells the real story, and no two are exactly alike.

What "clinical autonomy" typically means in practice: the DSO controls the business side — scheduling systems, fee schedules, insurance credentialing, marketing, staffing protocols, and purchasing decisions. You retain the clinical decision-making within your operatories, in theory. In practice, the line blurs when the DSO sets production targets that create implicit pressure to treatment plan in ways that maximize billable procedures, or when they limit the materials and labs you can use, or when they push for scheduling protocols that reduce your time per patient. None of this is necessarily sinister — it's just the reality of a managed business model. You need to decide, honestly, whether that model suits the way you want to practice.

Independent buyers, by contrast, are typically buying the practice specifically because they want to run it their way. They may want to preserve your protocols, or they may want to change everything. But they're not answering to a private equity board or a corporate compliance department. The question isn't which model is objectively better — it's which one matches what you care about. If your clinical philosophy and the way you treat patients is central to your sense of identity as a dentist, that matters. If you're genuinely ready to step back from the business decisions and just practice dentistry until you're done, DSO employment has real appeal.

Side-by-Side Comparison

Factor	DSO Sale	Independent Sale
Valuation multiple (EBITDA)	4–8× (PE-backed platforms higher)	3–5× (market rate)
Cash at close	70–90% of purchase price	90–100% (minus seller financing)
Earnout risk	Common — 10–25% of deal	Rare; simpler if included
Equity roll option	Often offered or required	Not applicable
Close timeline	60–120 days (cash buyer)	6–12 months (loan process)
Closing certainty	Very high	Moderate (financing contingency)
Post-sale employment	2–5 year associate agreement common	6–18 month transition typical
Clinical autonomy	Limited by management services agreement	Full (buyer runs practice)
Administrative burden after close	Largely eliminated	Eliminated at close
Staff culture impact	Corporate integration — mixed outcomes	Continuity likely; buyer-dependent
Patient relationship continuity	Variable; depends on DSO model	Generally strong
Tax flexibility	Less allocation flexibility	More control over asset allocation

Administrative Burden and What You're Actually Buying Back

One underappreciated advantage of a DSO affiliation is what you stop being responsible for after the deal closes. Running a solo dental practice means you're a dentist and a small business owner simultaneously — managing HR, negotiating with insurers, handling payroll and benefits, dealing with equipment vendors, managing marketing, staying current on regulatory compliance, and absorbing whatever administrative crisis comes up on a given Tuesday. That burden is real, and it compounds over time. By the end of a long career, many dentists describe the administrative weight as a bigger source of burnout than the clinical work itself.

Under a DSO, those responsibilities transfer to the corporate infrastructure. You show up, you practice dentistry, you go home. The billing department handles denials and appeals. HR handles the employee situation. Purchasing handles the supply chain. For many dentists who are genuinely tired of the business side, this is not a minor benefit — it's a significant quality-of-life improvement in whatever years of practice remain after the sale. It's worth valuing explicitly when you're weighing the deal.

With an independent sale, administrative burden disappears at close — you're fully out, typically after a short transition period. This is the clean-break option. If full retirement is what you're after, an independent sale gets you there faster and more completely than most DSO employment agreements. The DSO employment model keeps you in the building, which means some version of the administrative reality will creep back in even if the formal responsibilities are gone. The colleague politics, the corporate directives, the production meetings — these are new administrative experiences that replace the old ones, not simply their elimination.

Staff Retention: What Actually Happens to Your Team

Your clinical team is one of the most valuable assets in your practice — arguably more important to patient retention than any equipment or technology you've acquired. Patients stay loyal to hygienists, assistants, and front desk staff they've known for years. When a transition disrupts that team, collections suffer in ways that show up immediately and persist longer than most sellers anticipate. How your team fares post-close should be a serious factor in your deal evaluation, not an afterthought.

With an independent buyer, staff continuity tends to be higher — particularly in the early period after transition. Individual dentists who are buying their first or second practice understand that the team is what they're buying along with the goodwill and equipment. They're typically motivated to retain your staff and are willing to invest in that relationship. The risk is that individual buyers vary in management quality; a new owner who struggles with team leadership can cause more attrition than a corporate transition would have.

DSO acquisitions have a more complicated track record with staff. The honest answer is that it varies enormously by DSO and by practice. Larger national platforms that are in acquisition mode across multiple markets sometimes bring in regional managers, change benefit structures, and apply scheduling and production protocols that feel foreign and demoralizing to staff who've been part of a boutique practice culture for years. Smaller, doctor-founded DSOs that are genuinely trying to grow thoughtfully often handle integration better. The way to assess this is simple: ask the DSO for references from dentists who've sold to them in the past two years, and then specifically ask those dentists what happened to their staff. Attrition numbers don't lie. If the DSO can't or won't provide references from recently acquired practices, take that as meaningful data.

Patient Relationships and the Continuity Question

Patient retention post-transition is one of the most reliable predictors of how well the practice performs after close — which matters to you if you have an earnout, and matters to the buyer regardless of deal structure. Most practices lose some patients through any transition, but the difference between losing 5% and losing 20% of your active base is enormous in dollar terms, and it's substantially influenced by how the transition is handled.

Individual buyers who are personally committed to the practice tend to support better patient retention outcomes because they can be introduced personally, maintain continuity of care, and communicate with patients in a way that feels like a human handoff rather than a corporate acquisition. The letter from you to your patients, introducing the new doctor — who is right there in the office — has a different emotional resonance than a notice that your practice has been acquired by a corporate group.

DSO patient communication is typically more scripted and institutional. Some DSOs do this thoughtfully and invest in messaging that emphasizes continuity. Others are efficient but impersonal. In either case, patients who've been coming to you for twenty years because of the relationship will notice a difference. The ones who are loyal to you personally — particularly elderly patients with health complexity and long histories — are the ones most at risk of leaving. This isn't a reason to avoid a DSO sale, but it is a reason to negotiate the transition communication approach as part of the deal rather than leaving it entirely to the DSO's standard playbook.

Transition Timelines: Speed vs. Fit

The speed difference between DSO and independent transactions is substantial and underappreciated. DSOs are professional acquirers with dedicated M&A teams, established legal frameworks, and institutional capital. Once they've decided they want your practice, they can move from letter of intent to closing in 60–120 days. There are no SBA loan timelines, no lender appraisals, no financing contingencies. For a seller who needs liquidity quickly — whether because of health, burnout, or family circumstances — this speed is a genuine advantage.

Independent sales run on a different calendar. Finding the right buyer takes time: listing with a broker, qualifying interested parties, waiting for financing approval from a lender who requires their own independent appraisal, navigating due diligence requests from buyers who are making the largest financial decision of their lives and want to be thorough. From active marketing to close, six to twelve months is typical. Longer timelines mean more months of uncertainty, more risk that the deal falls through on a financing contingency, and more time during which the confidentiality of your sale is at risk.

That said, the time an independent sale takes is also time during which you can be selective. You're not locked into one buyer's valuation methodology or one DSO's management services agreement. You can run a competitive process with multiple qualified buyers, take your time assessing fit, and walk away from buyers whose post-close plans don't align with what you care about. If maximizing fit — for your team, your patients, your community — matters more than speed, the longer timeline is not a cost; it's an investment in getting the right outcome.

Post-Sale Obligations: What You're Actually Agreeing To Stay For

Every dental practice sale includes a period during which the selling dentist stays on after close, but the shape and duration of that period is dramatically different between DSO and independent transactions — and it has a bigger impact on your post-sale quality of life than most dentists realize when they're signing the purchase agreement.

In an independent sale, the transition period is typically 3 to 18 months. You introduce the new owner to your patients, help transfer clinical knowledge, provide mentorship during the learning curve, and gradually reduce your schedule until you're done. For most sellers, this feels like a natural wind-down. The new owner is running the business; you're just providing continuity. The exit ramp has a clear end point, and when it's done, you're done.

In a DSO transaction, "employment after close" can mean something much more substantial. Many DSO deals include employment agreements of 2–5 years, and some are structured around the assumption that you'll continue as a productive clinician for the full term. The compensation is typically a percentage of production (often 25–35%) or a market-rate associate salary — which sounds reasonable until you realize that you are now an employee of the entity you just sold to, working under a management services agreement you signed, in a practice you no longer own, answering to a regional manager. For some dentists, this is exactly what they wanted: fewer responsibilities, a guaranteed paycheck, no ownership risk. For others, it feels like a significant downgrade from running their own shop. Be honest with yourself about which camp you're in before you sign.

Running Both Processes: Why the Best Sellers Often Explore Both

The most sophisticated approach — and the one that gives you the most negotiating leverage — is to run a parallel process where you're simultaneously engaged with DSO acquirers and independent buyer prospects. This isn't as complex as it sounds, and it doesn't require you to be deceptive with either side. You're simply evaluating your options before committing to a path, which is exactly what any prudent seller should do.

What this looks like in practice: engage a dental practice broker who has experience with both transaction types and ask them to approach the market on both fronts simultaneously. They can manage confidentiality across both buyer pools and help you structure a comparison that goes beyond headline price — modeling after-tax proceeds, earnout risk-adjusted value, equity roll scenarios, and total compensation over your expected employment period. When you have real competing offers, you also have negotiating leverage with both sides that you wouldn't have if you were exclusively committed to one path early in the process.

Many dentists who go through this process find that the decision clarifies itself once real numbers and real terms are on the table. Abstract discussions about DSO vs. independent feel very different from comparing a specific DSO's management services agreement and compensation plan against a specific independent buyer's letter of intent and post-close plan. The decision is much easier to make when it's grounded in actual offers rather than hypotheticals. Give yourself the information you need to make it well.

Non-Compete Agreements and Geographic Restrictions

Both DSO and independent transactions will include non-compete provisions, but the scope and practical impact can differ significantly. In an independent sale, the non-compete is typically defined by a geographic radius (often 5–15 miles from the practice location) and a time period (typically 2–5 years) during which you cannot practice dentistry or own a competing practice nearby. These are negotiable, and for a dentist who is genuinely retiring, they're largely irrelevant — you're not planning to open a competing practice in your old backyard.

DSO non-competes can be broader and more consequential. If you sign a multi-year employment agreement with a DSO and that relationship becomes untenable — if the culture turns out to be nothing like what was represented, or if the DSO makes management decisions you find clinically or ethically objectionable — you may find yourself unable to practice in your own market for years after leaving. Non-competes in employment agreements can apply even if the employer terminates you without cause. Have your attorney review the non-compete provisions of the DSO employment agreement with the same scrutiny you'd apply to the purchase price. The geographic and temporal scope, what constitutes a violation, and what the DSO's enforcement history has been are all material considerations.

The Bottom Line: Both Paths Are Legitimate — Your Job Is to Choose the Right One

The DSO vs. independent debate is not a question of which path is objectively better. It is a question of which path is better for you, given what you actually want from this transaction and what comes after it. The dentist who is ten years from retirement, wants to keep practicing without the management headaches, and is financially comfortable taking some earnout risk has a genuinely different calculus than the dentist who is 62, wants to be fully retired in 18 months, and cares deeply about what happens to the staff he's worked with for two decades.

Be honest with yourself about your priorities before you engage with any buyer. Write them down in order: price, speed, staff continuity, patient relationships, clinical autonomy, administrative relief, timeline to full retirement, post-sale income. Knowing which of those matter most to you and in what order will make every decision in the transaction process clearer. You'll know immediately which deal terms are dealbreakers and which are just negotiating points.

And then get the right advisors. A dental-specific transaction attorney, a CPA experienced with healthcare practice sales, and a broker who has actually closed transactions on both the DSO and independent side. The complexity of these deals — the earnout structures, the equity roll analysis, the tax allocation negotiations, the management services agreement review — is real, and it's expensive to get wrong. The advisory fees are not a cost; they're insurance against the most expensive mistakes you can make in the single largest financial transaction of your career.

Do this right. You've spent decades building something worth selling. The care you bring to the exit should match the care you brought to the practice.